
Ketamine for depression – evidence and proposals for practice

PERSPECTIVES

TOR-MORTEN KVAM

tor-morten.kvam@so-hf.no

Tor-Morten Kvam, specialist in psychiatry and senior consultant at North Østfold District Psychiatric Centre, Moss outpatient clinic, and affiliated with the Psychiatric Research Group and the PsykForsk research team at Østfold Hospital Trust.

The author has completed the ICMJE form and declares no conflicts of interest.

LOWAN H. STEWART

Lowan H. Stewart, specialist in emergency medicine, medical advisor for the PsykForsk research team, Østfold Hospital Trust, and medical director at AxonKlinikken.

The author has completed the ICMJE form and declares the following conflicts of interest: He runs a private clinic that treats depression with ketamine.

ANDREAS WAHL BLOMKVIST

Andreas Wahl Blomkvist, specialty registrar in addiction medicine at the Department of Substance Use and Specialised Psychiatric Services, University Hospital of North Norway.

The author has completed the ICMJE form and declares no conflicts of interest.

OLE A. ANDREASSEN

Ole A. Andreassen, specialist in psychiatry and senior consultant, professor and head of SFF NORMENT, University of Oslo and Oslo University Hospital.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received lecture fees from Lundbeck and Sunovion, and serves as a consultant to HealthLytix.

Current treatment for serious depression is unsatisfactory, and many patients fail to achieve the desired effect. Ketamine represents a new treatment option, and randomised trials show a rapid effect of intravenous ketamine. Although knowledge about adverse effects and the duration of the effect is somewhat deficient, we believe that the time has come to start clinical treatment in Norway.




Illustration: Åge Peterson

Several treatment options for depression are currently available, both pharmacological and psychological, but severe depression is difficult to treat, and a considerable proportion of patients fail to achieve remission. New treatment options are therefore urgently needed. Ketamine is a well-known anaesthetic that in a number of studies has proven to have a fast-acting antidepressant effect with acceptable adverse effects, although its durability needs to be clarified [\(1\)](#). A nasal spray containing the enantiomer esketamine was recently approved for use against treatment-resistant depression. More knowledge is needed on both the duration of the effect and the adverse effects [\(1\)](#), but many patients with severe depression might still benefit from ketamine. A pilot project has therefore been initiated at Østfold Hospital, and we propose that coordinated clinical treatment be undertaken in Norway.

Depression and available treatment

In Norway, the lifetime prevalence of depressive disorders is approximately 17 % [\(2\)](#), which is consistent with the international prevalence, and depression is ranked third in the global burden of disease [\(3\)](#). In addition, it entails an increased risk of suicide. The effect of antidepressants, mainly selective serotonin reuptake inhibitors (SSRI), is only seen after 2–4 weeks, and the effect size is small to moderate [\(4\)](#). Approximately one-half of patients with depression do not respond to first-line treatment, and approximately 30 % show no response after multiple types of treatment [\(5\)](#). Treatment-resistant depression, defined as a lack of response to at least two types of antidepressants with adequate dosage and duration, is a serious condition [\(6\)](#). The existing antidepressants were developed in the 1980 s and 90 s, and few drugs have become available since then.

Ketamine

Ketamine consists of a racemic mixture of arketamine and esketamine and is a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist which produces a dosage-dependent analgesic and dissociative effect. Ketamine has been approved as an anaesthetic in Norway since 1972. How the blocking of the NMDA receptor affects depression is not fully known, but appears to include release of glutamate, neuroplasticity and synaptogenesis, as well as an effect on brain connectivity [\(7\)](#).

Ketamine for depression

A single dose of subanaesthetic intravenous racemic ketamine has been shown to be effective against depression in more than 20 double-blind, randomised controlled trials (DB-RCT) and a number of meta-analyses [\(8\)](#). The effect normally appears within 1–2 days, and the response and remission rates are 70 % and 30 % respectively within 24 hours [\(8\)](#). After a single dose, relapse within 1–2 weeks is the rule, although in 19–34 % of patients the effect seems to last beyond 30 days [\(8\)](#). The evidence base for the effect of repeated doses is limited. A number of open studies have shown increasing response and remission rates during a treatment series, which indicates that some patients need repeated treatments to achieve the full effect. A double-blind, randomised controlled trial for treatment-resistant depression showed that a dose repeated two or three times per week was effective when compared to placebo [\(9\)](#), while another double-blind, randomised controlled trial in a patient sample with chronic suicidality and treatment-resistant depression, of which nearly one-half had tried electroconvulsive therapy (ECT), showed no effect when compared to placebo [\(10\)](#).

Ketamine treatment also appears to have a rapid-onset effect on suicidality. Two meta-analyses of mainly small trials with short follow-up times show a beneficial effect on suicidal thoughts that are partly independent of the antidepressant effect [\(11, 12\)](#).

Adverse effects and risk

The adverse effects of ketamine are mainly of a mental, cognitive, neurological, urogenital or haemodynamic nature. They are dose-dependent, mild and most often transient – serious adverse effects are rare [\(13\)](#). The most common adverse effects usually subside within a few hours after the treatment, and include dissociation, increased pulse rate and blood pressure, blurred vision, sedation, headache, restlessness, dizziness and nausea. The patient should be thoroughly informed in advance of the possibility of dissociation and psychotomimetic effects. Iatrogenic ketamine addiction is rarely observed in outpatient administration of ketamine for treatment of depression, but is a factor to be aware of. Ketamine has been thoroughly tested as an anaesthetic, and the risk of a cardiovascular or respiratory effects in subanaesthetic doses when used for treatment of depression is considerably lower than when used in anaesthesia.

Indications and contraindications

In light of incomplete long-term data on efficacy and adverse effects, international guidelines recommend restricting intravenous ketamine to treatment-resistant depression [\(8\)](#). This is the same indication as for esketamine nasal spray.

Psychiatric contraindications include psychosis and type 1 bipolar disorder in the hypomanic/manic phase. Other relative contraindications are uncontrolled hypertension, cardiovascular disease, respiratory disease and pregnancy/breastfeeding. A further relative contraindication is drug addiction, although no increased risk of addiction has so far been documented for the use of ketamine in treatment of depression [\(1\)](#).

Practical use

Guidelines have been drawn up for the practical use of ketamine in the United States and Canada [\(8, 14\)](#). Here, the treatment is provided in outpatient clinics by doctors who have training in the use of ketamine. The presence of anaesthesia personnel during the treatment is not considered necessary, but when the drug is administered outside of the hospital, equipment required for cardiopulmonary resuscitation and health professionals experienced in its use should be available. Intravenous infusion, which makes for optimal bioavailability, with doses between 0.5 mg/kg and 1.0 mg/kg given over

40 minutes, is the most common form of administration. Oxygen saturation, blood pressure and pulse rate should be monitored. The short half-life means that the patients can go home within one hour after the infusion.

Drug approval

Intravenous ketamine for treatment of depression cannot be patented, and the pharmaceutical industry has therefore no incentive to undertake costly clinical trials to obtain a marketing permit. Esketamine nasal spray on the other hand is patented, and Janssen has invested in clinical trials that gave a basis for approval for treatment-resistant depression, including in Norway [\(15\)](#). No trials have yet compared esketamine nasal spray with intravenous ketamine, but a meta-analysis indicates that intravenous administration has a better effect [\(16\)](#). In the pilot project at Østfold Hospital, the intravenous form was used in light of its efficacy, procurement cost and anti-suicidal effect.

Proposal for focus areas

Many questions remain to be answered about the long-term effects of ketamine, optimal dosage, frequency of administration, patient selection and the underlying pharmacological mechanisms [\(1\)](#). However, there is solid evidence that ketamine is effective for treatment-resistant depression and has an acceptable adverse effect profile [\(1\)](#). To prevent uncoordinated experimentation with possible unfortunate consequences, we propose a national collaboration to ensure establishment of a shared evidence-based practice in Norway. Since long-term data from clinical trials are lacking, experiences from clinical use in a naturalistic setting should be systematically collected. The professional guidelines from the North American medical communities should be revised and adapted to Norwegian conditions [\(8, 14\)](#).

LITERATURE

1. McIntyre RS, Rosenblat JD, Nemeroff CB et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. *Am J Psychiatry* 2021; 178: 383–99. [PubMed][CrossRef]
2. Reneflot A, Aarø LE, Aase H et al. Psykisk helse i Norge. Oslo: Folkehelseinstituttet, 2018.
https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2018/psykisk_helse_i_norge2018.pdf Accessed 14.9.2021.
3. Knudsen AK, Tollånes MC, Haaland ØA et al. Sykdomsbyrde i Norge 2015. Resultater fra Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015). Oslo: Folkehelseinstituttet, 2017.

https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2015/sykdomsb yrde_i_norge_2015.pdf Accessed 14.9.2021.

4. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018; 391: 1357–66. [PubMed][CrossRef]
5. Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. *CNS Drugs* 2009; 23: 627–47. [PubMed]
6. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatr Clin North Am* 1996; 19: 179–200. [PubMed][CrossRef]
7. Moda-Sava RN, Murdock MH, Parekh PK et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. *Science* 2019; 364: eaat8078. [PubMed]
8. Swainson J, McGirr A, Blier P et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. *Can J Psychiatry* 2021; 66: 113–25. [PubMed][CrossRef]
9. Singh JB, Fedgchin M, Daly EJ et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. *Am J Psychiatry* 2016; 173: 816–26. [PubMed][CrossRef]
10. Ionescu DF, Bentley KH, Eikermann M et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. *J Affect Disord* 2019; 243: 516–24. [PubMed][CrossRef]
11. Wilkinson ST, Ballard ED, Bloch MH et al. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. *Am J Psychiatry* 2018; 175: 150–8. [PubMed][CrossRef]
12. Witt K, Potts J, Hubers A et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. *Aust N Z J Psychiatry* 2020; 54: 29–45. [PubMed][CrossRef]
13. Acevedo-Diaz EE, Cavanaugh GW, Greenstein D et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. *J Affect Disord* 2020; 263: 568–75. [PubMed][CrossRef]
14. Sanacora G, Frye MA, McDonald W et al. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry* 2017;

74: 399–405. [PubMed][CrossRef]

15. Statens legemiddelverk. Spravato (esketamin) neseppray skal kun utleveres etter rekvisisjon fra sykehus.

<https://legemiddelverket.no/nyheter/spravata-esketamin-neseppray-skall-kun-utleveres-etter-rekvisisjon-fra-sykehus> Accessed 14.9.2021.

16. Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. *J Affect Disord* 2021; 278: 542–55. [PubMed][CrossRef]

Publisert: 25 October 2021. Tidsskr Nor Legeforen. DOI: 10.4045/tidsskr.21.0480

Received 8.6.2021, first revision submitted 23.8.2021, accepted 14.9.2021.

Copyright: © Tidsskriftet 2026 Downloaded from tidsskriftet.no 12 February 2026.